2005–2010 Resolutions

Adopted at the USP Convention 2005
March 13, 2005

  1. Public Monographs and Reference Materials
    USP resolves to work with appropriate stakeholders to contribute to the public health and patient care by eliminating barriers to expanding and updating public monographs in USP–NF and, if needed, developing reference materials for all legally marketed therapeutic products in the U.S.
  2. Integrity and Safety of Therapeutic Products
    USP resolves to work with stakeholders to continue to develop packaging, shipping, distribution, and storage standards and practices that ensure the integrity and safety of all therapeutic products through the distribution and dispensing system. USP further resolves to support educational and allied activities, at all levels of distribution, dispensing, and administration (manufacturer through patient) concerning the integrity and safety of therapeutic products.
  3. New Science and Technology
    USP resolves to work with appropriate stakeholders to track emerging sciences and technologies, and when appropriate, to develop information, best practices, and standards that have direct applications to the public health and patient care.
  4. Compounding Standards and Education
    USP resolves to expand its work with appropriate parties involved in compounding, including practitioners, FDA, state boards of pharmacy, and other regulatory authorities, to support and disseminate information about science-based compounding practice.
  5. Standards for Nomenclature and Labeling
    USP resolves to collaborate with appropriate partners to continue establishing standards for labeling and nomenclature that support the safe and proper use of therapeutic products, including but not limited to initiatives that:
    • Provide references for the identification of multi-ingredient products.
    • Address recurring medication errors, particularly in the area of look-alike/sound-alike names, labeling, and packaging.
    • Reduce medication errors, particularly in the area of look-alike/sound-alike names, by encouraging the use, in the practice setting, of only the generic names for new single active-ingredient products marketed after January 1, 2006.
    • Encourage the uniform use of USP–NF dosage form nomenclature.
  6. USP International Presence
    USP resolves to continue working with international governmental and nongovernmental bodies to increase the impact of its public health programs internationally. Furthermore, USP resolves to provide assistance in improving regulatory mechanisms and in building capacity to monitor drug quality for countries that lack appropriate resources.
  7. International Harmonization
    USP resolves to continue its efforts to harmonize compendial standards with the Pharmacopeial Discussion Group (PDG) and other pharmacopeias.
  8. Drug Information Programs
    USP resolves to work with interested parties to develop information programs concerning therapeutic products for special patient populations in need of targeted information.
  9. Promoting Safe Medication Use and Disposal
    USP resolves to work with appropriate constituencies to continue developing programs to promote safe medication use and disposal.
  10. Evidence-based Methodologies and Algorithms for Decision Support Used in E-Prescribing and Pharmacy Computer Systems
    USP resolves to work with appropriate stakeholders to continue developing evidence-based methodologies and algorithms for decision support in areas such as drug–drug interactions, and to expand efforts to other alerts and recommendations for use in e-prescribing technologies and pharmacy computer systems. Furthermore, USP resolves to explore the feasibility and advisability of extending this approach to other information domains in the interest of the public health and patient care.
  11. USP Convention
    Using the recommendations of the Resolution 18 Committee to the Board of Trustees, USP charges the Council of the Convention, as an ongoing responsibility, to review the purpose, role, and composition of the Convention membership and examine the voting procedures used during the Convention.
  12. Expanded Outreach
    USP resolves to expand its efforts to engage stakeholders, who are affected by USP standards, but have not been fully involved in USP processes, including but not limited to Human Biologics, Animal Health, Biotechnology, and Device Manufacturers, in USP committees and programs.
  13. Organizational Outreach
    USP resolves to expand its efforts to engage pharmacy and other healthcare practitioner organizations in discussions related to USP's public health program activities. Efforts should be made to continue this dialogue on a regular, periodic basis to help build understanding among all organizations.

Read the full 2005-2010 resolutions.  (371KB)